Compare $ENSC vs $OTLC | Chartloom

Compare

$ENSC vs $OTLC

Ensysce Biosciences Inc · Oncotelic Therapeutics Inc

ENSC

Ensysce Biosciences Inc

OTLC

Oncotelic Therapeutics Inc

Compare $ENSC vs $OTLC

Comparing Ensysce Biosciences Inc and Oncotelic Therapeutics Inc

ENSCEnsysce Biosciences Inc

OTLCOncotelic Therapeutics Inc

ENSCEnsysce Biosciences Inc

Market cap

$8M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-39.3%

YTD performance

-43.9%

52W performance

-78.6%

FCF yield

-116.0%

OTLCOncotelic Therapeutics Inc

Market cap

$9M

P/E (TTM)

0.04x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-74.0%

52W performance

-76.9%

FCF yield

-16.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ENSC

OTLC

Detailed metrics comparison

ENSC

Ensysce Biosciences Inc

OTLC

Oncotelic Therapeutics Inc

Market Cap

ENSC$8M

OTLC$9M

Enterprise Value

ENSC$7M

OTLC$23M

Price

ENSC$0.53

OTLC$0.02

P/E Ratio

ENSCN/A

OTLC0.04x

P/S Ratio

ENSC1.72x

OTLC36.91x

EV/Sales

ENSC1.61x

OTLC91.75x

EV/EBITDA

ENSC0.00x

OTLC0.00x

P/B Ratio

ENSC2.39x

OTLC0.04x

P/FCF Ratio

ENSCN/A

OTLCN/A

EV/FCF

ENSC-0.81x

OTLC-15.05x

PEG Ratio

ENSCN/A

OTLCN/A

Forward P/E (NTM)

ENSCN/A

OTLCN/A

Forward P/S (NTM)

ENSCN/A

OTLCN/A

Revenue (TTM)

ENSC$5M

OTLC$250K

Revenue Growth (YoY)

ENSC-39.3%

OTLCN/A

Forward Rev Growth

ENSC-45.7%

OTLC0.0%

Gross Margin (TTM)

ENSC0.0%

OTLC83.1%

Operating Margin (TTM)

ENSC0.0%

OTLC0.0%

EBITDA Margin (TTM)

ENSC-197.8%

OTLC-1545.3%

Net Margin (TTM)

ENSC-280.5%

OTLC99875.6%

FCF Margin (TTM)

ENSC-199.5%

OTLC-609.8%

Net Income (TTM)

ENSC$-13M

OTLC$250M

FCF (TTM)

ENSC$-9M

OTLC$-2M

EPS (TTM)

ENSC-$0.97

OTLC$0.53

ROE (TTM)

ENSC-37496.0%

OTLC139.7%

ROA (TTM)

ENSC-32046.0%

OTLC91.8%

ROIC (TTM)

ENSC-33277.0%

OTLC129.6%

Cash

ENSC$677K

OTLC$186K

Debt

ENSC$197K

OTLC$14M

Net Cash/Debt

ENSC$480K

OTLC$-14M

Current Ratio (TTM)

ENSC0.70x

OTLC0.08x

Quick Ratio (TTM)

ENSC0.37x

OTLC0.01x

Debt/Equity (TTM)

ENSC0.10x

OTLC0.05x

Debt/Assets (TTM)

ENSC0.0%

OTLC0.0%

Interest Coverage (TTM)

ENSCN/A

OTLCN/A

Net Debt/EBITDA (TTM)

ENSC0.00x

OTLC0.00x

Beta

ENSC1.10

OTLC-0.07

52W Performance

ENSC-78.6%

OTLC-76.9%

YTD Performance

ENSC-43.9%

OTLC-74.0%

% from 52W High

ENSC-80.8%

OTLC-81.1%

% from 52W Low

ENSC129.1%

OTLC4.0%

Asset Turnover (TTM)

ENSC1.14x

OTLC0.00x

FCF Yield (TTM)

ENSC-116.0%

OTLC-16.5%

Earnings Yield (TTM)

ENSC-163.1%

OTLC2706.0%

Dividend Yield (TTM)

ENSCN/A

OTLCN/A

Rule of 40

ENSC-238.8

OTLC-609.8

EV/GP/RG

ENSCN/A

OTLCN/A

Ticker research

View ENSC research View OTLC research

Metric	ENSC Ensysce Biosciences Inc	OTLC Oncotelic Therapeutics Inc
Market & Valuation
Market Cap	$8M	$9M
Enterprise Value	$7M	$23M
Price	$0.53	$0.02
P/E Ratio	N/A	0.04x
P/S Ratio	1.72x	36.91x
EV/Sales	1.61x	91.75x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.39x	0.04x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.81x	-15.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$5M	$250K
Revenue Growth (YoY)	-39.3%	N/A
Forward Rev Growth	-45.7%	0.0%
Profitability
Gross Margin (TTM)	0.0%	83.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-197.8%	-1545.3%
Net Margin (TTM)	-280.5%	99875.6%
FCF Margin (TTM)	-199.5%	-609.8%
Net Income (TTM)	$-13M	$250M
FCF (TTM)	$-9M	$-2M
EPS (TTM)	-$0.97	$0.53
ROE (TTM)	-37496.0%	139.7%
ROA (TTM)	-32046.0%	91.8%
ROIC (TTM)	-33277.0%	129.6%
Financial Health
Cash	$677K	$186K
Debt	$197K	$14M
Net Cash/Debt	$480K	$-14M
Current Ratio (TTM)	0.70x	0.08x
Quick Ratio (TTM)	0.37x	0.01x
Debt/Equity (TTM)	0.10x	0.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.10	-0.07
52W Performance	-78.6%	-76.9%
YTD Performance	-43.9%	-74.0%
% from 52W High	-80.8%	-81.1%
% from 52W Low	129.1%	4.0%
Efficiency & Yields
Asset Turnover (TTM)	1.14x	0.00x
FCF Yield (TTM)	-116.0%	-16.5%
Earnings Yield (TTM)	-163.1%	2706.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-238.8	-609.8
EV/GP/RG	N/A	N/A
Ticker research	View ENSC research	View OTLC research

Valuation

P/E Ratio

OTLC

0.04x

P/S Ratio

ENSC

1.72x

OTLC

36.91x

EV/FCF

OTLC

-15.05x

ENSC

-0.81x

Growth & revenue

Revenue Growth TTM

ENSC

-39.3%

Forward Revenue Growth

OTLC

0.0%

ENSC

-45.7%

Profitability & performance

Gross Margin

OTLC

83.1%

ENSC

0.0%

ROE

OTLC

139.7%

ENSC

-37496.0%

FCF Yield %

OTLC

-16.5%

ENSC

-116.0%

52-Week Performance

OTLC

-76.9%

ENSC

-78.6%

Detailed metrics comparison

ENSC

Ensysce Biosciences Inc

OTLC

Oncotelic Therapeutics Inc

Market Cap

ENSC$8M

OTLC$9M

Enterprise Value

ENSC$7M

OTLC$23M

Price

ENSC$0.53

OTLC$0.02

P/E Ratio

ENSCN/A

OTLC0.04x

P/S Ratio

ENSC1.72x

OTLC36.91x

EV/Sales

ENSC1.61x

OTLC91.75x

EV/EBITDA

ENSC0.00x

OTLC0.00x

P/B Ratio

ENSC2.39x

OTLC0.04x

P/FCF Ratio

ENSCN/A

OTLCN/A

EV/FCF

ENSC-0.81x

OTLC-15.05x

PEG Ratio

ENSCN/A

OTLCN/A

Forward P/E (NTM)

ENSCN/A

OTLCN/A

Forward P/S (NTM)

ENSCN/A

OTLCN/A

Revenue (TTM)

ENSC$5M

OTLC$250K

Revenue Growth (YoY)

ENSC-39.3%

OTLCN/A

Forward Rev Growth

ENSC-45.7%

OTLC0.0%

Gross Margin (TTM)

ENSC0.0%

OTLC83.1%

Operating Margin (TTM)

ENSC0.0%

OTLC0.0%

EBITDA Margin (TTM)

ENSC-197.8%

OTLC-1545.3%

Net Margin (TTM)

ENSC-280.5%

OTLC99875.6%

FCF Margin (TTM)

ENSC-199.5%

OTLC-609.8%

Net Income (TTM)

ENSC$-13M

OTLC$250M

FCF (TTM)

ENSC$-9M

OTLC$-2M

EPS (TTM)

ENSC-$0.97

OTLC$0.53

ROE (TTM)

ENSC-37496.0%

OTLC139.7%

ROA (TTM)

ENSC-32046.0%

OTLC91.8%

ROIC (TTM)

ENSC-33277.0%

OTLC129.6%

Cash

ENSC$677K

OTLC$186K

Debt

ENSC$197K

OTLC$14M

Net Cash/Debt

ENSC$480K

OTLC$-14M

Current Ratio (TTM)

ENSC0.70x

OTLC0.08x

Quick Ratio (TTM)

ENSC0.37x

OTLC0.01x

Debt/Equity (TTM)

ENSC0.10x

OTLC0.05x

Debt/Assets (TTM)

ENSC0.0%

OTLC0.0%

Interest Coverage (TTM)

ENSCN/A

OTLCN/A

Net Debt/EBITDA (TTM)

ENSC0.00x

OTLC0.00x

Beta

ENSC1.10

OTLC-0.07

52W Performance

ENSC-78.6%

OTLC-76.9%

YTD Performance

ENSC-43.9%

OTLC-74.0%

% from 52W High

ENSC-80.8%

OTLC-81.1%

% from 52W Low

ENSC129.1%

OTLC4.0%

Asset Turnover (TTM)

ENSC1.14x

OTLC0.00x

FCF Yield (TTM)

ENSC-116.0%

OTLC-16.5%

Earnings Yield (TTM)

ENSC-163.1%

OTLC2706.0%

Dividend Yield (TTM)

ENSCN/A

OTLCN/A

Rule of 40

ENSC-238.8

OTLC-609.8

EV/GP/RG

ENSCN/A

OTLCN/A

Ticker research

View ENSC research View OTLC research

Metric	ENSC Ensysce Biosciences Inc	OTLC Oncotelic Therapeutics Inc
Market & Valuation
Market Cap	$8M	$9M
Enterprise Value	$7M	$23M
Price	$0.53	$0.02
P/E Ratio	N/A	0.04x
P/S Ratio	1.72x	36.91x
EV/Sales	1.61x	91.75x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.39x	0.04x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.81x	-15.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$5M	$250K
Revenue Growth (YoY)	-39.3%	N/A
Forward Rev Growth	-45.7%	0.0%
Profitability
Gross Margin (TTM)	0.0%	83.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-197.8%	-1545.3%
Net Margin (TTM)	-280.5%	99875.6%
FCF Margin (TTM)	-199.5%	-609.8%
Net Income (TTM)	$-13M	$250M
FCF (TTM)	$-9M	$-2M
EPS (TTM)	-$0.97	$0.53
ROE (TTM)	-37496.0%	139.7%
ROA (TTM)	-32046.0%	91.8%
ROIC (TTM)	-33277.0%	129.6%
Financial Health
Cash	$677K	$186K
Debt	$197K	$14M
Net Cash/Debt	$480K	$-14M
Current Ratio (TTM)	0.70x	0.08x
Quick Ratio (TTM)	0.37x	0.01x
Debt/Equity (TTM)	0.10x	0.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.10	-0.07
52W Performance	-78.6%	-76.9%
YTD Performance	-43.9%	-74.0%
% from 52W High	-80.8%	-81.1%
% from 52W Low	129.1%	4.0%
Efficiency & Yields
Asset Turnover (TTM)	1.14x	0.00x
FCF Yield (TTM)	-116.0%	-16.5%
Earnings Yield (TTM)	-163.1%	2706.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-238.8	-609.8
EV/GP/RG	N/A	N/A
Ticker research	View ENSC research	View OTLC research